Robeco Institutional Asset Management B.V. Sells 24,172 Shares of IQVIA Holdings Inc. $IQV

Robeco Institutional Asset Management B.V. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 151,293 shares of the medical research company’s stock after selling 24,172 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.09% of IQVIA worth $40,675,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of IQVIA during the second quarter worth $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of IQVIA by 9.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after acquiring an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of IQVIA by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock valued at $282,657,000 after acquiring an additional 66,643 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of IQVIA during the 2nd quarter valued at $240,911,000. Finally, Bank of America Corp DE bought a new stake in IQVIA during the 2nd quarter worth $235,551,000. Institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 over the last three months. Insiders own 1.70% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent research reports. Royal Bank Of Canada upped their target price on IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Mizuho lifted their price target on IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Robert W. Baird boosted their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Finally, UBS Group began coverage on IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $276.00.

IQVIA Trading Up 0.6%

NYSE IQV opened at $278.25 on Friday. The business’s 50-day moving average price is $263.12 and its two-hundred day moving average price is $215.98. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $282.98. The firm has a market capitalization of $45.80 billion, a PE ratio of 24.35, a price-to-earnings-growth ratio of 2.43 and a beta of 1.17. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 11.55 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.